In doing so, CytoSorb will help Converge Biotech strengthen its existing intensive care unit (ICU) portfolio to now include the treatment of sepsis and other life-threatening diseases. With ...

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Shock reversal has not been used as a primary outcome in randomised trials before, therefore, sample size calculation was based on a heterogeneous population of patients with sepsis from a limited ...

Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention ...

Early signs of sepsis may include severe pain, shortness of breath, and mental confusion. Sepsis starts with an infection in any part of the body and spreads through the blood. When this happens, your ...

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the ...

Sepsis is a life-threatening clinical syndrome characterized by multiorgan dysfunction caused by a dysregulated or over-reactive host response to infection. During sepsis, the coagulation cascade is ...

CytoSorb, our flagship product, which is approved in the European Union, is used primarily to treat life-threatening conditions in the intensive care unit and cardiac surgery such as sepsis ...

Phillip Chan; Chief Executive Officer, Director; Cytosorbents Corp. Peter Mariani; Chief Financial Officer; Cyt ...